课题基金 / 基金详情

项目摘要

项目成果

ALLAN H CONNEY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Sunlight-induced skin cancer is the most prevalent cancer in the United States. In earlier studies we treated SKH-1 mice with UVB twice a week for 20 weeks. These initiated mice have no tumors, but they have a high risk of developing tumors during the next several months (high risk mice). Topical applications of caffeine 5 days a week to these high risk mice inhibited carcinogenesis and selectively increased apoptosis in the tumors but not in areas of the epidermis away from the tumors. Our leading hypothesis is that caffeine induces apoptosis by inhibition of the ATR/Chk1-dependent G2/M cell cycle checkpoint leading to premature mitosis and cell death. In preparation for translational studies on the effects of caffeine in humans, we evaluated the tumorigenicity of four commercial moisturizing creams that are commonly used by the public. All four had tumorigenic activity when applied topically for several months to high risk mice. To overcome this obstacle, we developed a novel Custom Blend cream that lacks tumorigenic activity and can be used for translational studies in humans. We plan to pursue the following specific aims: 1. Determine the effects of topical applications of caffeine in our newly developed non-tumorigenic Custom Blend cream on carcinogenesis in UVB-pretreated high risk SKH-1 mice and study the effects of the treatment on apoptosis, proliferation and the ATR/Chk1 signal transduction pathway in focal hyperplastic areas of the epidermis and in tumors. The effects of oral administration of caffeine will also be studied. 2. Determine the primary targets or early events for the action of caffeine by studying its effect on key molecular markers based on Aim 1 in epidermal focal hyperplastic areas and tumors after short term treatment (e.g. with topically applied caffeine for 3 hr, 6 hr, 24 hr, 48 hr, 7 days, or 14 days). 3. Initiate a translational study to determine the effects of topical applications of caffeine on apoptosis, proliferation and the ATR/Chk1 pathway in actinic keratoses in human skin. Key molecular markers identified by research in Aim 1 will be determined in biopsies of large keratoses before and after two weeks of topical applications of caffeine or placebo. PUBLIC HEALTH RELEVANCE:Our proposed mechanistic studies on the effects of caffeine on ultraviolet light-induced cancer formation are important steps on the road to the development of a novel approach for the prevention of sunlight-induced skin cancer. Our studies on the effects of caffeine may also have importance for individuals ingesting caffeine-containing beverages and chocolate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibition of skin cancer by caffeine: Effects on late stages of carcinogenesis
  • 批准号:
    8069892
  • 项目类别:
  • 资助金额:
    $28.05万
  • 财政年份:
    2008
  • 负责人:
    ALLAN H CONNEY
  • 依托单位:
Inhibition of skin cancer by caffeine: Effects on late stages of carcinogenesis
  • 批准号:
    7648264
  • 项目类别:
  • 资助金额:
    $28.92万
  • 财政年份:
    2008
  • 负责人:
    ALLAN H CONNEY
  • 依托单位:
Inhibition of skin cancer by caffeine: Effects on late stages of carcinogenesis
  • 批准号:
    7515196
  • 项目类别:
  • 资助金额:
    $30.28万
  • 财政年份:
    2008
  • 负责人:
    ALLAN H CONNEY
  • 依托单位:
Effect of caffeine on UVB-induced skin cancer
  • 批准号:
    7847543
  • 项目类别:
  • 资助金额:
    $27.4万
  • 财政年份:
    2006
  • 负责人:
    ALLAN H CONNEY
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: